consumo de fármacos en el periodo de hemodiálisis en niños con
TRANSCRIPT
AUTORES: Ortiz MI*1,2, Gayosso-Domínguez X1, Cortés-López J1,
Romo-Hernández G1, López-Cadena JM1,2, Copca-García JA1
1. Hospital del Niño DIF, Pachuca, Hidalgo; 2. Área Académica de Medicina del ICSA, UAEH, Pachuca, Hidalgo, México.
Congress 53rd Annual Meeting of the Western Pharmacology Society 2010
Proceedings of a meeting held 7-10 February 2010, San Diego, California,
USA.
DRUG USE IN THE PERIOD OF HEMODIALYSIS IN CHILDREN WITH
END-STAGE RENAL DISEASE IN A MEXICAN PEDIATRIC HOSPITAL
CONSUMO DE FÁRMACOS EN EL PERIODO DE HEMODIÁLISIS EN
NIÑOS CON ENFERMEDAD RENAL EN ETAPA TERMINAL EN UN
HOSPITAL PEDIÁTRICO MEXICANO
Área del Conocimiento: 3 Medicina y Ciencias de la Salud
Abstract
Chronic renal failure (CRF) requiring dialysis or transplantation is known as end-stage
renal disease (ESRD). Several drugs are used in treating the symptoms, comorbid
conditions and treatment side effects of ESRD. We performed a study to investigate the
drug use during the period of hemodialysis in children with ESRD in the Hospital del
Niño DIF, Pachuca, Hidalgo, Mexico. Data were collected from clinical expedients of the
Hospital. The data included demographic, clinical data and those on drugs usage. A
total of 13 patients were included. The average age of patients was 14.2 2.1 years.
Data were collected and 18 different drugs were given to the pediatric patients. The
mean number of drugs during the period of hemodialysis was 1.3 0.6 (1-4). Two-
hundred sixteen doses of medication were administered in 130 hemodialysis sessions
to the patients. The drugs most used were erythropoietin (42.7 %), followed by dextrose
solution (18.9 %), calcium gluconate (10.4 %), iron dextran (9.1%) and nifedipine (5.5
%). Medications may be used to help control some of the issues associated with kidney
failure or hemodialysis. Our study showed that few drugs are administered to children
with ESRD during their period of hemodialysis.
Key words: Chronic Renal Failure
Área del Conocimiento: 3 Medicina y Ciencias de la Salud
ResumenInsuficiencia renal crónica (IRC) que requiere diálisis o trasplante se conoce como enfermedadrenal en etapa terminal (ESRD). Varios medicamentos se utilizan en el tratamiento de lossíntomas, la comorbilidad y los efectos secundarios del tratamiento de la enfermedad renalterminal. Se realizó un estudio para investigar el uso de drogas durante el periodo dehemodiálisis en niños con enfermedad renal terminal en el Hospital del Niño DIF, Pachuca,Hidalgo, México. Los datos fueron recolectados a partir de expedientes clínicos del Hospital. Losdatos que se incluyen datos demográficos, clínicos y aquellos sobre el uso de drogas. Un totalde 13 pacientes fueron incluidos. La edad media de los pacientes fue de 14,2 2,1 años. Losdatos fueron recolectados y 18 diferentes drogas fueron entregadas a los pacientes pediátricos.El número medio de fármacos durante el periodo de hemodiálisis fue de 1,3 0,6 (1-4).Doscientos dieciséis dosis de medicamentos se administraron en 130 sesiones de hemodiálisis alos pacientes. Los medicamentos más utilizados fueron la eritropoyetina (42,7%), seguido desolución de dextrosa (18,9%), gluconato de calcio (10,4%), hierro dextrano (9,1%) y nifedipina(5,5%). Se pueden utilizar medicamentos para ayudar a controlar algunos de los problemasasociados con la insuficiencia renal o hemodiálisis. Nuestro estudio mostró que algunosmedicamentos se administran a los niños con enfermedad renal terminal durante el período dehemodiálisis.
Key words: Insuficiencia Renal Crónica
Área del Conocimiento: 3 Medicina y Ciencias de la Salud
Introduction
Healthy kidneys remove excess fluid, minerals and wastes. Renal failure is a situation in which
the kidneys fail to function adequately. When kidney function has deteriorated and is no longer
adequate to sustain life and the process is considered irreversible, renal replacement therapy—
dialysis or transplantation—becomes necessary to maintain life. Chronic kidney failure, also
called end-stage renal disease (ESRD), is the most feared consequence of kidney disease.
Specific treatments are dependent upon the underlying diseases.
Our objective was performed a study to investigate the drug use during the period of
hemodialysis in children with ESRD in the Hospital del Niño DIF, Pachuca, Hidalgo, Mexico.
•Data were collected from charts of the Hospital del
Niño DIF, Pachuca, Hidalgo, Mexico.
•The data included demographic, clinical data and
those on drugs usage.
•A total of 13 patients with ESRD were included
METHODS
RESULTS•A total of 13 patients (8 male and 5 female) were included.
•The average age of patients was 14.2 2.1 years.
•The average number of hemodialysis sessions to the patients was 78.8 ± 1.9
•Data were collected and 18 different drugs were given to the pediatric patients.
•The mean number of drugs during the period of hemodialysis was 1.3 0.6 (1-4).
•Two-hundred sixteen doses of medication were administered in 130 hemodialysis
sessions to the patients.
•The most used were erythropoietin (42.7 %), followed by dextrose solution (18.9
%), calcium gluconate (10.4 %), iron dextran (9.1%) and nifedipine (5.5 %).
The mean age of patients was 14.2 2.1 years
The mean weight of patients before hemodialysis was 41.8 7.8 kg
Figure 1. Percentage of female andmale patients
Male
Female
The mean weight of patients after hemodialysis was 39.9 7.4 kg
RESULTS
Figure 2. Drugs commonly used in the patientsduring hemodialysis
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0
Percentage
Erythropoietin
Dextrose
Calcium gluconate
Iron dextran
Nifedipine
Figure 3. Drugs commonly used in the patientsduring hemodialysis
0.0 0.5 1.0 1.5 2.0 2.5
Percentage
Bicarbonate
Ranitidine
Ipratropium/Salbutamol
Adrenaline
Ketorolac
Amikacin
RESULTS
Figure 4. Drugs commonly used in the patients during hemodialysis
0.0 0.2 0.4 0.6 0.8 1.0
Percentage
Concentrated sodium
Vancomicin
Atropine
Midazolam
Paracetamol
Hyoscine butylbromide
RESULTS
CONCLUSIONS
MEDICATIONS MAY BE USED TO HELP CONTROL SOME OF
THE ISSUES ASSOCIATED WITH KIDNEY FAILURE OR
HEMODIALYSIS.
OUR STUDY SHOWED THAT FEW DRUGS ARE
ADMINISTERED TO CHILDREN WITH ESRD DURING THEIR
HEMODIALYSIS PERIOD
References1. Wühl, E., Schaefer, F. (2008) Pediatr. Nephrol. 23, 705-716.
2. Rahman, M., Smith, M.C. (1998) Arch. Intern. Med. 158, 1743-152.
3. Moudgil, A., Bagga, A. (1999) Indian J. Pediatr. 66, 241-253.
4. Nahas, W.C., David-Neto, E. (2009) Pediatr. Transplant. 13, 524-535.
5. Osborn, G., Escofet, X., Da Silva, A. (2008) Cochrane Database Syst.
Rev. 8, CD002786.
6. Jean, G., Terrat, J.C., Vanel, T., Hurot, J.M., Lorriaux, C., Mayor, B.,
Chazot, C. (2008) Nephrol. Dial. Transplant. 23, 3670-3676.
7. Shrestha, S., Ghotekar, L.R., Sharma, S.K., Shangwa, P.M., Karki, P.
(2008) JNMA J. Nepal Med. Assoc. 47, 1-6.
8. Tozawa, M., Iseki, K., Fukiyama, K. (2000) Clin. Exp. Nephrol. 4, 236-240.
9. Possidente, C.J., Bailie, G.R., Hood, V.L. (1999) Am. J. Health Syst.
Pharm. 56, 1961-1964.
10. Hamid, H., Ahmed, I., Shabbir, A., Hafeez, F., Maqbool, S. (2003) Pak.
Paed. J. Sep. 27, 108-112.
